Table 6 Impact of the treatment phase on the annual ambulatory healthcare expenditures attributable to diabetes for patients with T2DM with normal renal function (€) (Adjusted model on differences in expenditures between T2-DM patients and matched individuals without diabetes)
From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
Treatment phases (ref = monotherapy) | Pharmacy | Consultations | Medical devices | Nursing cares | Others | Total ambulatory costs |
|---|---|---|---|---|---|---|
Double therapy | 238*** | 9*** | 26*** | 9 | −31 | 224*** |
(213;262) | (6;12) | (15;38) | (-5;23) | (-71;9) | (169;280) | |
Triple therapy | 556*** | 16*** | 35** | −30* | −131*** | 411*** |
(509;603) | (11;21) | (13;57) | (-56;-4) | (-208;-55) | (306;517) | |
Insulin therapy | 1,224*** | 78*** | 863*** | 1,236*** | 1,268*** | 3,807*** |
(1,190;1,259) | (74;82) | (847;880) | (1,217;1,256) | (1,212;1,325) | (3,730;3,885) |